Does trimetazidine reduce damage caused by Ischemia-Reperfusion Injury?
Ischemia-reperfusion injury (IRI) happens when blood flow returns to tissue after a period of lack of oxygen, causing additional damage. Trimetazidine is a drug used for angina that may protect cells during this process. Research in animals and some human contexts suggests it can reduce injury, but more studies are needed to confirm its benefits in people.
What the research says
A 2022 review of organ preservation found that trimetazidine is among the pharmacological molecules that have shown the most benefit in preclinical studies for reducing IRI, and it is already in clinical use for other conditions 5. A 2024 rat study showed that trimetazidine (20 mg/kg for seven days) reduced liver damage caused by mesenteric artery IRI, lowering markers of oxidative stress and cell death 6. Another review on cardiovascular conditions noted that trimetazidine may protect against IRI by targeting ferroptosis, a type of cell death involved in heart damage 1. However, most evidence comes from animal models, and large human trials are still needed to confirm these effects in patients.
What to ask your doctor
- Could trimetazidine be helpful for my condition involving ischemia-reperfusion injury?
- Are there any ongoing clinical trials testing trimetazidine for organ protection?
- What are the potential side effects or interactions of trimetazidine?
- How does trimetazidine compare to other treatments for reducing IRI?
- Is trimetazidine appropriate for my specific health situation?
This question is drawn from common patient questions about this topic and answered using cited medical research. We do not provide individualized advice.